on INTRASENSE (EPA:ALINS)
Intrasense announces its 2024 half-year turnover
Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announced a turnover of €1,203 thousand for the first half of 2024, marking a decrease of 45% compared to the same period in 2023.
The decrease in activity is explained by geopolitical factors in Eastern Europe and an anti-corruption campaign in China. Despite this, Intrasense is preparing to bounce back by focusing on more stable areas with high potential.
The company obtained CE marking for Myrian® 2.12, integrating AI algorithms for lungs and prostate. In addition, the new Liflow® platform dedicated to oncological imaging has been certified, opening new commercial perspectives.
Intrasense is reorganizing, notably with the arrival of Jérôme Thiebaud as Chief Business Officer. The objective remains to double turnover by 2026 and achieve operational balance.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INTRASENSE news